Russian Heart Failure Journal 2009year Comparative efficacy of levosimendan and dobutamine in improving major echocardiographic, hemodynamic and neuro-humoral parameters in patients with IHD and CHF


To access this material please log in or register

Register Authorize
2009/

Comparative efficacy of levosimendan and dobutamine in improving major
echocardiographic, hemodynamic and neuro-humoral parameters in patients with IHD and CHF

Rakhimov A. Z., Kamardinov D. Kh., Tugeeva E. F., Matskeplishvili S.T., Buziashvili Yu. I.

Keywords:

DOI:

Urgency. A therapeutic strategy in patients with CHF should be focused on stabilization of their condition, improvement of prognosis and quality of life due to reduced symptoms and requirement of repeated hospitalizations. In this setting, non-glycoside inotropic drugs are mandatory. Thus the non-glycoside inotropic drug, the calcium sensitizer levosimendal is of a great practical interest. Aim. Studying clinical effects of levosimendan compared to a traditional non-glycoside drug, dobutamine as a part of multimodality treatment in patients with IHD and CHF. Materials and methods. 52 patients with IHD complicated with CHF and LV systolic dysfunction (LV EF <40%) were evaluated. Group 1 (n=27) included patients who received a single daily infusion of 12.5 mg levosimendan solution in addition to their drug therapy; group 2 (n=25) consisted of patients who received a single daily infusion of 750 mg dobutamine solution. General clinical examination, ECG, echoCG, and tetrapolar chest impedancemetry were performed and plasma level of brain natriuretic peptide (BNP) was measured in all patients. Patients were examined at baseline, 15 minutes after the beginning of drug infusion, at 3 days, 1, 3 and 5 months. Results. Levosimendan significantly improved the LV systolic function, hemodynamic parameters and decreased BNP levels. Compared to dobutamine, the effect of levosimendan persisted for a longer time. While the effect of dobutamine rapidly disappeared after the end of infusion (effects were not seen in 3 days) effects of levosimendan remained for at least 3 days and some of them remained up to 1 month. Levosimendan exerted a less potent but much more prolonged inotropic effect than dobutamine and was undoubtedly superior to dobutamine by vasodilation and duration of hemodynamic effects. Beneficial effects of levosimendan on the neuro-humoral profile of IHD patients with CHF are its definite advantage over dobutamine.
  1. Krumholz H, Parrent E, Tu N et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997; 157 (1):99‑104.
  2. McAlister F, Lawson F, Teo K et al. A systemic review of randomized trials of disease management programs in heart failure. Am J Med. 2001; 110 (5):378‑384.
  3. Cuffe M, Califf R, Adams K et al. Effects of short-term, intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287 (12):1541–1547.
  4. Cleland J, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail. 1999; 1 (3):229‑241.
  5. Jaagosild P, Dawson N, Thomas C et al. Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. Arch Intern Med. 1998; 158 (10):1081–1089.
  6. Беленков Ю. Н., Мареев В. Ю., Скворцов А. А. Левосимендан – новое средство для лечения декомпенсированных больных с тяжёлой хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2004; 5 (3):120‑125.
  7. Felker G, O’Conner C. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J. 2001; 142 (3):393‑401.
  8. Packer M, Carver J, Rodeheffer R et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1992; 326 (23):1565–1566.
  9. Tancja T, Johnson M, Gheorghiade M. Current status of acute intravenous therapy for chronic heart failure exacerbations. Conges Heart Fail. 1999; 5:199‑207.
  10. Givertz M, Andreou C, Conrad C. Direct myocardial effects of levosimendan, a novel calcium sensitizing agent, in humans with left ventricular dysfunction. Circulation. 1998; 98 (Suppl.):1–579.
  11. Kaheinen P, Pollesello P, Levijoki J et al. Effects of levosimendan and milrinone on oxygen consumption in isolated guinea – pig heart. J Cardiovasc Pharmacol. 2004; 43 (4):555‑561.
  12. Sorsa T, Pollesello P, Rosevear P et al. Stereoselective binding of levosimendan to cardiac troponin C causes Ca (2+) – sensitization. Eur J Pharmacol. 2004; 486 (1):18.
  13. Nieminen M, Sandell E, Vuorinen J, et al. A multicenter dose – finding study on the effects of continuous infusion of levosimendan on cardiac output in patients with congestive heart failure. Internal report: Orion Pharma; 1998 October 26. Report No.: 300105.
  14. Nijhawan N, Nicolosi A, Montgomery M, et al. Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo – controlled trial. J Cardiovasc Pharmacol. 1999; 34 (2):219‑228.
  15. Bowman P, Haikala H, Paul R. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther. 1999; 288 (1):316‑325.
  16. Lilleberg J, Nieminen M, Akkila J et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19 (4):660‑668.
  17. Haikala H, Kaheinen P, Levijoki J et al. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res. 1997; 34 (3):536‑546.
  18. Kaheinen P, Haikala H. Levosimendan and milrinone increase diastolic coronary flow through opening of the ATP – sensitive potassium channels by different mechanism of action. J Am Coll Cardiol. 1998; 31 (Suppl. C):31С.
  19. Nieminen M, Akkila J, Hasenfuss G et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36 (6):1903–1912.
  20. Kivikko M, Antila S, Eha J et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol. 2002; 42 (1):43–51.
  21. Lehtonen L. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Expert Opin Invest Drugs. 2001; 10 (5):955‑970.
  22. Mebazaa A, Nieminen M, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297 (17):1883–1891.

To access this material please log in or register

Register Authorize
Ru En